Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 1
2021 1
2022 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
[Female urinary incontinence: diagnosis and treatment].
Humburg J. Humburg J. Ther Umsch. 2019;73(9):535-540. doi: 10.1024/0040-5930/a001038. Ther Umsch. 2019. PMID: 31113313 Review. German.
For OAB or UUI also physiotherapy as well as medications such as antimuscarinics or the recently released beta-3-adrenoreceptor-agonist Mirabegron are well established. In case of failure intravesical botox application is a good option....
For OAB or UUI also physiotherapy as well as medications such as antimuscarinics or the recently released beta-3-adrenoreceptor-agonist M …
Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial.
Hsiao SM, Tu FC, Su TC, Wu PC, Lin HH. Hsiao SM, et al. Sci Rep. 2022 Aug 20;12(1):14219. doi: 10.1038/s41598-022-18391-6. Sci Rep. 2022. PMID: 35987885 Free PMC article. Clinical Trial.
There were 87 women (mirabegron, n = 43; and solifenacin, n = 44) who completed 12-week treatment and underwent heart rate variability examination. ...In conclusion, solifenacin might decrease blood pressure, and mirabegron might increase heart rate. Nonetheless, th …
There were 87 women (mirabegron, n = 43; and solifenacin, n = 44) who completed 12-week treatment and underwent heart rate variabilit …
Anticholinergic Burden and Associated Healthcare Resource Utilization in Older Adults with Overactive Bladder.
Jaggi A, Nazir J, Fatoye F, Quelen C, Tu X, Ali M, Siddiqui E, Covernton PJO, Landeira M, Choudhury N. Jaggi A, et al. Drugs Aging. 2021 Oct;38(10):911-920. doi: 10.1007/s40266-021-00884-0. Epub 2021 Aug 13. Drugs Aging. 2021. PMID: 34386936 Free PMC article.
Mean (SD) ACB scores in the post-index period were 1.2 (1.3) and 2.5 (1.7) in those treated with mirabegron (beta-3 agonist) or bladder anticholinergics, respectively. LIMITATIONS: The generalizability of the results outside the UK is unclear. ...
Mean (SD) ACB scores in the post-index period were 1.2 (1.3) and 2.5 (1.7) in those treated with mirabegron (beta-3 agonist) or bladd …
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, Schermer CR. Herschorn S, et al. Health Qual Life Outcomes. 2018 Apr 19;16(1):69. doi: 10.1186/s12955-018-0892-0. Health Qual Life Outcomes. 2018. PMID: 29673355 Free PMC article. Clinical Trial.
BACKGROUND: The PREFER study was an assessment of medication tolerability, treatment preference and symptom improvement during treatment with mirabegron (M) and tolterodine (T) extended release (ER) in patients with overactive bladder (OAB). ...A higher percentage of patie …
BACKGROUND: The PREFER study was an assessment of medication tolerability, treatment preference and symptom improvement during treatment wit …
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR. Staskin D, et al. Int Urogynecol J. 2018 Feb;29(2):273-283. doi: 10.1007/s00192-017-3377-5. Epub 2017 Jun 15. Int Urogynecol J. 2018. PMID: 28620791 Free PMC article. Clinical Trial.
INTRODUCTION AND HYPOTHESIS: The objective of this study was to assess the tolerability and treatment preference in patients with overactive bladder (OAB) treated with mirabegron or tolterodine. METHODS: This was a two-period, 8-week crossover, double-blind, phase IV study …
INTRODUCTION AND HYPOTHESIS: The objective of this study was to assess the tolerability and treatment preference in patients with overactive …
Serial patent litigation: an emerging strategy to delay entry of generic competition.
Bonis T, Kesselheim AS, Tu S. Bonis T, et al. Health Aff Sch. 2025 Dec 17;3(12):qxaf240. doi: 10.1093/haschl/qxaf240. eCollection 2025 Dec. Health Aff Sch. 2025. PMID: 41487439 Free PMC article.
In the case of Astellas's overactive bladder drug mirabegron (Myrbetriq), after an initial Hatch-Waxman case settled in 2020 with generic entry expected in 2024, Astellas pursued 4 additional lawsuits, each built on new but substantively indistinguishable patents. ...
In the case of Astellas's overactive bladder drug mirabegron (Myrbetriq), after an initial Hatch-Waxman case settled in 2020 with gen …